37
Participants
Start Date
February 15, 2024
Primary Completion Date
March 1, 2026
Study Completion Date
September 1, 2026
Belantamab mafodotin 2.5 mg/kg (8 weeks)
2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
Belantamab mafodotin 1.9 mg/kg (8 weeks)
1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
Belantamab mafodotin 1.4 mg/kg (12 weeks)
1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Belantamab mafodotin 1.9 mg/kg (12 weeks)
1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages
Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
Belantamab mafodotin 1.0 mg/kg (12 weeks)
1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
NOT_YET_RECRUITING
Mayo Clinic, Rochester
RECRUITING
UT Southwestern Medical Center, Dallas
NOT_YET_RECRUITING
Stanford Cancer Institute, Stanford
NOT_YET_RECRUITING
Tufts Medical Center, Inc., Boston
NOT_YET_RECRUITING
Dana-Farber Cancer Institute, Boston
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Texas Southwestern Medical Center
OTHER